image description

Tag: lupus therapeutics

To Increase Diversity in Lupus Clinical Research, Project CHANGE Launches Pilot Programs in Atlanta, Nashville, and Philadelphia

NEW YORK, NY, June 29, 2023 — The clinical research affiliate of the Lupus Research Alliance, Lupus Therapeutics, launched three pilot research initiatives for Project CHANGE, a community-driven approach to address systemic challenges contributing to the underrepresentation of people of color, particularly Black people, in lupus clinical trials. Emory University in Atlanta, Vanderbilt University in Nashville, […] Read More

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, NY, June 2, 2023 — Lupus Research Alliance clinical research affiliate Lupus Therapeutics will collaborate with Novartis Pharmaceuticals Corporation to conduct  three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America. Read More

Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […] Read More

Lupus Research Alliance Appoints New Executive Vice President of Clinical Research Affiliate Lupus Therapeutics

NEW YORK, NY. January 17, 2023— The Lupus Research Alliance (LRA) announced the appointment of Stacie J. Bell, PhD as Executive Vice President to lead the organization’s clinical research affiliate Lupus Therapeutics (LT). Dr. Bell comes to Lupus Therapeutics with 25+ years of experience in discovery research, clinical development, and patient engagement in the biopharmaceutical […] Read More

Data at ACR 2022 Shows Lupus Research Alliance Peer Education Program Increases Intentions to Join Clinical Trials Among Diverse Patient Population

NEW YORK, NY–November 8, 2022 — The Lupus Research Alliance and clinical researchaffiliate Lupus Therapeutics will present data at ACR Convergence 2022 showing that the pilot peer education program Patient Advocates for Lupus Studies (PALS), increased knowledge, perception, and intentions among people with Systemic Lupus Erythematosus (SLE) to participate in clinical trials. These study results […] Read More

Long-time Supporter LADA Donates $150,000 to LRA-Funded Research

August 29, 2022 Big thanks go to the Lupus and Allied Diseases Association, Inc. (LADA) for their donation of $150,000 to support research funded by the Lupus Research Alliance given at their 22nd Annual Lupus Charity Golf Classic at Shenendoah Golf Course at Turning Stone in upstate New York. LADA President & CEO Kathleen A. […] Read More

LRA Brings Encouraging News from European Rheumatology Meeting

June 2, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results presented at the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress from a Phase 2 trial of its investigational biologic deucravacitinib for the treatment of systemic lupus erythematosus (SLE). Deucravacitinib […] Read More

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] Read More

Encouraging Results with Obinutuzumab for Lupus Nephritis

February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY.  A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […] Read More

Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research

NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and clinical affiliate Lupus Therapeutics (LT) announced two major initiatives improving  representation of minorities in clinical trials and  the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The LRA has been addressing these disparities for many years and now proudly launches this […] Read More